Glycogen Synthase Kinase-3 (GSK-3)–Targeted Therapy and Imaging
Mukesh K. Pandey and Timothy R. DeGrado
Theranostics 2016, Vol. 6, Issue 4

In a 2016 review about GSK-3 inhibitors, Pandey and DeGrado showed the enzime imaging studies, with the designe of inhibitor's, as a powerful instrument to study inhibitors that can selectively target
individual pathways and differentiate between the phosphorylated and non-phosphorylated forms of
GSK-3. These studies ca evaluate drugs candidates based on noninvasive imaging measurements
of the target-to-background ratios.

A recent Review: "Recent advances in understanding the cellular roles of GSK-3" Cormier KW and Woodgett JR. Recent advances in understanding the cellular roles of GSK-3 [version 1; referees: 3 approved] F1000Research 2017, 6(F1000 Faculty Rev):167 (doi: 10.12688/f1000research.10557.1),  showed some pathways to inactivate  the enzyme. I´m trying to find other unusual way to inactivate GSK-3 because of our research about lithium and Alzheimer´s Disease. We used lithium microdose. In this Review Woodget sayd "Besides exploring the regulation of GSK-3 through association with scaffolding proteins and phosphorylation at S9/21, recent findings have explored GSK-3 regulation by other post-translational modifications". I´m very interested in this issue.

Publication

Hy
I´m back in my posts of GSK3 and Lithium.
Our paper was publishied in PLOSone in 2015:

"Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease"
Nowadays we are study the pathways of lithium efficacy in our work.

Our paper, about Lithium microdose in Alzhemer's disease was reffered and comented in Alzheimer's Drug Discovery Foundation. http://www.alzdiscovery.org/cognitive-vitality/report/lithium-dietary-and-supplement-doses
We are now developing other researchs about our favorite subject : Alzheimer's Disease and Lithium.

Gsk3 enzyme is one of the most interesting protein.  In Jope's paper about it, he showed us the caracteristic that gsk3 has of change it's way to work depending of the place that it is. If it is in the cytosolic compartiment it acts phosphorylating proteins that become active or inactive. If it is in the nucleus it acts in growing factors. Sometime thies enzyme is present in mithocondrias and acts in a survive or apoptotic way.
About this you can read Jope,2004.

We have a research group called GPNF in UNiversity of Faculdade de Ciências Médicas da SanTa Casa de São Paulo in São Paulo , Brazil. Our group studies Alzheimer's Disease and lithium in this disease. Our sponser Hudson Buck speake in a television program about our researches.
This speake is in this link http://www.youtube.com/watch?v=aObuymgo_3Q .

There is a lot of papers now a days presenting energy deficits as a mainly mecahanism in Alzheimer's Disease.
In these pathway our GSK3 always is present.
One of this papers is Tau Phosphorylation by GSK3 in Different Conditions, wroten by Jesús Avila et al,  in International Journal of Alzheimer’s Disease Volume 2012.
Evere day I have a huge surprise about this enzyme.